I.R.C.C.S. Fondazione Santa Lucia
hsantalucia.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
56
Active
18
Phase 3
1
Total enrollment
3,125
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rotigotine 4Mg/24Hrs Patch | — | — | — | — | 2 | ||
| Intra-articular infiltration | — | — | — | — | — | 1 |
Next readouts
- 2025-07
- 2025-11-01
Top conditions
- Stroke14
- Alzheimer Disease7
- Multiple Sclerosis7
- Parkinson Disease5
- Spinal Cord Injuries4
- Motor Disorders3
- Severe Traumatic Brain Injury2
- Rehabilitation2
Frequently asked questions about I.R.C.C.S. Fondazione Santa Lucia
- How many clinical trials does I.R.C.C.S. Fondazione Santa Lucia have on ClinicalTrials.gov?
- I.R.C.C.S. Fondazione Santa Lucia is listed as the lead sponsor on 56 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of I.R.C.C.S. Fondazione Santa Lucia's trials are in Phase 3?
- 1 of I.R.C.C.S. Fondazione Santa Lucia's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does I.R.C.C.S. Fondazione Santa Lucia focus on?
- I.R.C.C.S. Fondazione Santa Lucia's most-studied conditions on ClinicalTrials.gov are Stroke, Alzheimer Disease, Multiple Sclerosis, Parkinson Disease, Spinal Cord Injuries.
- When are I.R.C.C.S. Fondazione Santa Lucia's next clinical trial readouts?
- I.R.C.C.S. Fondazione Santa Lucia has 2 upcoming primary-completion readouts tracked here; the soonest is “A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease”, expected around 2025-07.